Showing results (241-250 of 353) with videos related to
Sort By:
Pageof 36
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 2, 2007
A phase I/II study of galiximab (an anti-CD80 monoclonal antibody) in combination with rituximab for relapsed or refractory, follicular lymphomaJ P Leonard, J W Friedberg, A Younes, et al.Leukemia & Lymphoma|January 25, 2013
Patterns of use of 18-fluoro-2-deoxy-D-glucose positron emission tomography for initial staging of grade 1-2 follicular lymphoma and its impact on initial treatment strategy in the National Comprehensive Cancer Network Non-Hodgkin Lymphoma Outcomes databaseKarim E Abou-Nassar, Ann Vanderplas, Jonathan W Friedberg, et al.Journal of General Internal Medicine|September 10, 2021
Effect of Peer Benchmarking on Specialist Electronic Consult Performance in a Los Angeles Safety-Net: a Cluster Randomized Trial, Daniella Meeker, Mark W Friedberg, et al.JACC. Cardiooncology|May 22, 2024
Impact of Preexisting Heart Failure on Treatment and Outcomes in Older Patients With Hodgkin LymphomaJenica N Upshaw, Jason Nelson, Benjamin Sweigart, et al.Journal of the National Cancer Institute|December 18, 2016
Beyond RCHOP: A Blueprint for Diffuse Large B Cell Lymphoma ResearchGrzegorz S Nowakowski, Kristie A Blum, Brad S Kahl, et al.The Lancet. Oncology|July 22, 2014
Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b studyAnas Younes, Catherine Thieblemont, Franck Morschhauser, et al.Leukemia & Lymphoma|January 14, 2016
A phase II study of belinostat (PXD101) in relapsed and refractory aggressive B-cell lymphomas: SWOG S0520Soham D Puvvada, Hongli Li, Lisa M Rimsza, et al.British Journal of Haematology|October 23, 2015
Phase II trial of R-CHOP plus bortezomib induction therapy followed by bortezomib maintenance for newly diagnosed mantle cell lymphoma: SWOG S0601Brian G Till, Hongli Li, Steven H Bernstein, et al.Cancer|October 19, 2011
Lack of benefit of central nervous system prophylaxis for diffuse large B-cell lymphoma in the rituximab era: findings from a large national databaseAnita Kumar, Ann Vanderplas, Ann S LaCasce, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 10, 2022
The Advanced-Stage Hodgkin Lymphoma International Prognostic Index: Development and Validation of a Clinical Prediction Model From the HoLISTIC ConsortiumAngie Mae Rodday, Susan K Parsons, Jenica N Upshaw, et al.Pageof 36